Summary Safety Review - Hydroxyzine (ATARAX and generics) - Assessing the Potential Risk of Abnormal Heart Rhythm

A safety review was undertaken soon after the European Medicines Agency notified Health Canada of the possibility that the use of hydroxyzine products could be associated with abnormal changes in the electrical activity of the heart, such as QT interval prolongation.

Data and Resources

Additional Info

Field Value
Source
Version
Author
Author Email
Maintainer
Maintainer Email
Data Level
Agreement Required
Purpose Constraints
Redistribution Allowed
AI Training Allowed
Data Steward
Title (French) Résumé de l'examen de l'innocuité - Hydroxyzine (ATARAX et génériques) - Évaluation du risque potentiel d'anomalie du rythme cardiaque
Update Frequency as_needed
Geographic Scope []
Criticality Level []
Sensitivity Level unrestricted
Language
Contact Person
Contact Email
Data Dictionary
Open Canada Date Published 2020-12-07 00:00:00
Open Canada Date Modified
Open Canada Subject ["health_and_safety"]
Open Canada Keywords {"fr": ["Résumé de l'examen de l'innocuité", "Hydroxyzine", "ATARAX", "évaluation", "risque potentiel", "rythme cardiaque anormal", "changements anormaux", "activité électrique du cœur", "allongement de l'intervalle QT"], "en": ["Summary Safety Review", "Hydroxyzine", "ATARAX", "assessing", "potential risk", "abnormal heart rhythm", "abnormal changes", "electrical-activity of the-heart", "QT interval prolongation"]}
Open Canada Collection publication
Principal Organization
Reference Data
Official Source